ArticleCancer cell2020
The Evolution of Angiogenic and Inflamed Tumors: The Renal Cancer Paradigm.
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- BAP1 and PBRM1 Loss Is Associated with Aggressive Clinicopathological Features in Clear Cell Renal Cell Carcinoma: Prognostic Implications in a 10-Year Surgical Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Determinants of pancreatic tropism in metastatic renal cell carcinoma.JCI insight · 2026Article
- AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma.Cell reports. Medicine · 2025Article
- Determinants of late metastases in renal cell carcinoma.Journal of the National Cancer Institute · 2025Article
- Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial.Nature communications · 2025Article
- Conserved patterns of transcriptional dysregulation, heterogeneity, and cell states in clear cell kidney cancer.Cell reports · 2025Article
- Machine learning-based single-sample molecular classifier for cancer grading.Frontiers in oncology · 2025Article
- Histopathology Based AI Model Predicts Anti-Angiogenic Therapy Response in Renal Cancer Clinical Trial.ArXiv · 2024Article
- Distinct spatial landscapes in clear-cell renal cell carcinoma as revealed by whole transcriptome analysis.Immuno-oncology technology · 2024Article
- Article
- BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.Cancer immunology, immunotherapy : CII · 2023Article
- The expanding role of BAP1 in clear cell renal cell carcinoma.Human pathology · 2023Review
- Tumor-to-Tumor Metastases Involving Clear Cell Renal Cell Carcinomas: A Diagnostic Challenge for Pathologists Needing Clinical Correlation.Clinics and practice · 2023Article
- Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.Nature communications · 2022Article
- Article
- Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.Current urology reports · 2022Review
- Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy.Biomaterials · 2022Article
- Renal cell carcinoma and viral infections: A dangerous relationship?World journal of nephrology · 2022Review
- Improving Renal Tumor Biopsy Prognostication With BAP1 Analyses.Archives of pathology & laboratory medicine · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Gene expression analyses have identified subtypes of conventional renal cell carcinoma broadly distributed into angiogenic and proliferative/ immunogenic clades. Integration with genomic and functional experiments in animal models yields an evolutionary model. Evolutionary trajectories illustrate remarkable plasticity, particularly for a tumor that typically begins with inactivation of a single gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.